- ECM Partners and Metric Capital Partners sell majority stake in FAMAR to MidEuropa.
- FAMAR continues to serve a diversified client base with expanded capabilities.
![](https://pharmasource.global/wp-content/uploads/2024/07/Image-23-07-24-at-10.25-AM-1024x497.jpeg)
FAMAR, a contract development and manufacturing organisation (CDMO), has been acquired by MidEuropa, a European private equity investor. The agreement, signed by ECM Partners and Metric Capital Partners, marks a significant shift in FAMAR’s ownership structure.
The transaction, announced on July 22, 2024, involves MidEuropa acquiring a majority stake in FAMAR. ECM Partners initially engaged with FAMAR in 2020, recognizing its strong track record in customer service within the pharmaceutical sector. Over the past four years, ECM Partners implemented turnaround initiatives that expanded FAMAR’s offerings and fostered growth through strategic investments, particularly in research and development.
FAMAR currently serves a diversified blue-chip client base of pharmaceutical companies in over 80 international markets. The company provides a full-service offering across the CDMO value chain, including capabilities in sterile, solids, semi-solids, and R&D services. FAMAR employs approximately 1,900 people across six manufacturing sites in southern Europe, supported by two R&D centres.
Konstantinos Rengis, CEO of FAMAR, expressed optimism about the new partnership: “We are pleased to welcome MidEuropa as a strong and highly reputable healthcare investor who shares our vision and values. With their backing, we are well placed to further accelerate FAMAR’s growth, provide high-quality service to our customers and support our growing team while contributing to the health and well-being of millions of patients worldwide.”